化疗和放化疗同步治疗局部晚期非小细胞肺癌临床观察

目的 比较放化疗联合治疗与单纯化疗对局部晚期非小细胞肺癌(NSCLC)的临床疗效及安全性。方法 65例不能手术的NSCLC患者,分为单纯化疗组(A组)30例、放化疗联合组(B组)35例,A组给予紫杉醇联合顺铂方案化疗两周期,B组同A组并给予同步放疗方案。对比两组疗效及安全性。结果 A组治疗有效率、1年生存率分别为36.7%、30.0%,B组分别为65.7%、54.3%,B组较A组明显提高(χ2值分别为10.581和9.339,P<0.05)。患者治疗后主要不良反应为骨髓抑制及肝功能异常;A组白细胞减少、血小板减少和肝功能异常发生率分别为33.3%、3.3%和56.7%,B组则分别为36.6%、10.0%和60.0%,两组相比均无显著性差异(χ2值分别为2.011,0.007,2.206,P>0.05)。结论 局部晚期NSCLC放化疗联合治疗优于单纯化疗,不良反应能耐受。

Clinical observation of radiotherapy concurrently combined with chemotherapy for local advanced non-small cell lung cancer

Objective To compare the efficacy and adverse effects of radiotherapy currently combined with different chemotherapy for local advanced non-small cell lung cancer (NSCLC). Methods Sixty-five patients with NSCLC were divided into two groups. Group A was given taxol and cisplatin, and group B was given taxol and cisplatin combined with radiotherapy. The two groups were compared on the efficacy and safety. Results The total response (CR+PR) were 36.7% (group A) , 65.7% (group B),X2=10.581, P<0.05. The 1 year survival rates of group A were 30.0% and 54.3% of group B,X2=9.339, P<0.05. The adverse effects showed no significant difference (X2 value was 2.011, 0.007, 2.206 respectively, P0.05). Conclusion The radiotherapy concurrently combined with taxol and cisplatin chemotherapy for patients with NSCLC could be more effectively, and the patients could tolerate the side effects, this therapy method was secure and receivable.